RUBY:'A Huge Win' for Patients With Endometrial Cancer RUBY:'A Huge Win' for Patients With Endometrial Cancer
The RUBY trial shows that adding an immune checkpoint inhibitor to chemotherapy improved overall survival by over 1 year for women with advanced or recurrent endometrial cancer.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 19, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Immune Checkpoint Inhibitor-Chemo Combo Boosts OS in Advanced Endometrial Cancer
(MedPage Today) -- SAN DIEGO -- The addition of an immune checkpoint inhibitor (ICI) to chemotherapy up front improved overall survival (OS) in patients with advanced or recurrent endometrial cancer, regardless of mismatch repair (MMR) status... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 18, 2024 Category: Hematology Source Type: news
IGH Naturals begins clinical trial for product to ease chemotherapy side effects
Rocklin supplement company IGH Naturals Inc. has won approval to conduct a clinical study on the effectiveness of its food product to ease harsh side effects of chemotherapy in cancer patients. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 16, 2024 Category: Biotechnology Authors: Mark Anderson Source Type: news
Study Explores Safety of Removing Inoperable Pancreatic Tumors
A clinical trial will examine if chemotherapy followed by a novel surgical procedure can improve outcomes for patients with pancreatic tumors previously considered inoperable (Source: Disabled World)
Source: Disabled World - March 15, 2024 Category: Disability Tags: Pancreatic Cancer Source Type: news
New PD-1 Inhibitor Approved for Esophageal Cancer
(MedPage Today) -- The FDA approved tislelizumab (Tevimbra) for advanced/metastatic esophageal squamous cell carcinoma (ESCC) previously treated with chemotherapy, BeiGene announced.
The approval stipulates use of the PD-1 inhibitor in adults... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 15, 2024 Category: American Health Source Type: news
Targeted radiopharmaceuticals offer new hope for longer'healthspans '
Mark Crockett, MD, chief medical officer at TeleDaaS.Americans today can expect to live long lives. However, increased longevity has brought on a troubling rise in chronic disease, diminishing the quality of life later in life. A 2018 study from the U.S. Centers for Disease Control and Prevention (CDC) found that more than a quarter of U.S. adults now battle multiple chronic conditions, up from 22% in 2001. We may be living longer, but more Americans struggle through these extra years in poor health — presenting a pressing need to extend not just lifespans but “healthspans.”
An emerging field of precision radiopharm...
Source: AuntMinnie.com Headlines - March 15, 2024 Category: Radiology Tags: Molecular Imaging Source Type: news
FDA Approves New Esophageal Cancer Drug FDA Approves New Esophageal Cancer Drug
The checkpoint inhibitor is approved for second-line treatment of patients with esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-L1 inhibitor.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 15, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
A 5-Minute Quiz Revealed Olivia Munn ’ s Breast Cancer Risk. You Can Take It Too
Olivia Munn recently revealed in an Instagram post that a free, easy tool saved her life. Her ob-gyn used a questionnaire designed to calculate a person’s risk of breast cancer, which revealed Munn had an increased chance of developing the disease. That led to further tests and an early diagnosis of Luminal B cancer in both breasts and quick treatment.
The Breast Cancer Risk Assessment Tool, which her doctor used, isn’t new. It doesn’t involve any high-tech gadgets, doesn’t require a doctor, and doesn’t even cost anything. Experts say more women should know about it and complete it after th...
Source: TIME: Health - March 14, 2024 Category: Consumer Health News Authors: Time Tags: Uncategorized healthscienceclimate Source Type: news
QT Imaging to deliver Breast Acoustic CT scanner to research centers
QT Imaging Holdings is delivering its Breast Acoustic CT scanner in collaboration with research centers in the U.S. and Canada.
The company is collaborating with the Department of Radiation Oncology and Radiation Treatment Program at the Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, and the University of Illinois, Urbana-Champaign. This collaboration is part of a five-year research grant from National Institutes of Health/National Cancer Institute to develop an inexpensive, portable, safe, and repeatable imaging approach that can accurately identify early response of breast cancer patients to neoadjuvant ...
Source: AuntMinnie.com Headlines - March 14, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
No Benefit to Adding Chemotherapy in Older Adults With NSCLC No Benefit to Adding Chemotherapy in Older Adults With NSCLC
Adding chemotherapy to immunotherapy increased the adverse event burden without improving survival outcomes compared with immunotherapy alone in older adults with NSCLC.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 14, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Toward a Cure: Chemotherapy Plus TKI in EGFR-Mutant NSCLC Toward a Cure: Chemotherapy Plus TKI in EGFR-Mutant NSCLC
Dr Mark Kris discusses neoadjuvant approaches for patients non-small cell lung cancer with oncogenic drivers for which there are effective targeted therapies.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 13, 2024 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
Does breast radiation therapy raise risk of skin cancer?
Radiation therapy for breast cancer treatment leads to an increased risk of skin cancer, according to research published March 8 in JAMA Network Open.
A team led by Shawheen Rezaei from Stanford University found that the risk of non-keratinocyte skin cancer diagnosis such as melanoma and hemangiosarcoma after breast cancer treatment with radiation was more than 50% higher.
“Although occurrences of non-keratinocyte skin cancers are rare, physicians should be aware of this elevated risk to help inform follow-up care,” the Rezaei team wrote.
While breast cancer treatment strategies have improved over the decades, survi...
Source: AuntMinnie.com Headlines - March 11, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties Womens Imaging Breast Breast Imaging Source Type: news
Survival Up With Enfortumab Vedotin + Pembrolizumab in Urothelial Cancer
FRIDAY, March 8, 2024 -- For patients with previously untreated locally advanced or metastatic urothelial carcinoma, enfortumab vedotin and pembrolizumab yield significantly better survival than chemotherapy, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 8, 2024 Category: Pharmaceuticals Source Type: news
Neoadjuvant Chemo Adds Significant Treatment Benefit in Penile Cancer
THURSDAY, March 7, 2024 -- Neoadjuvant chemotherapy (NAC) with lymphadenectomy for locally advanced penile squamous cell carcinoma (PSCC) is well tolerated and improves outcomes, according to a study published online Feb. 16 in the Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 7, 2024 Category: Pharmaceuticals Source Type: news
First-Line Immunotherapy Alone Sufficient for Older NSCLC Patients, Study Suggests
(MedPage Today) -- Adding an immune checkpoint inhibitor (ICI) to chemotherapy for older patients with previously untreated advanced non-small cell lung cancer (NSCLC) provided no survival advantage compared with ICI therapy alone, according to... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 7, 2024 Category: Hematology Source Type: news